Print Page  Close Window


SEC Filings

S-1/A
OREXIGEN THERAPEUTICS, INC. filed this Form S-1/A on 04/09/2007
Entire Document
 
 

  1.37   PAYMENT TRANSFER FEES” shall have the meaning given in Section 3.05.
 
  1.38   PRE-CLINICAL STUDIES” shall have the meaning given in Section 4.02.
 
  1.39   PRE-COLLABORATION CYPRESS INTELLECTUAL PROPERTY” means all INTELLECTUAL PROPERTY owned by, either partially or wholly, or licensed to, or otherwise controlled by, CYPRESS, as of the EFFECTIVE DATE.
 
  1.40   PRE-COLLABORATION INTELLECTUAL PROPERTY” means the PRE-COLLABORATION CYPRESS INTELLECTUAL PROPERTY and/or PRE-COLLABORATION OREXIGEN INTELLECTUAL PROPERTY.
 
  1.41   PRE-COLLABORATION OREXIGEN INTELLECTUAL PROPERTY” means all OREXIGEN PATENT RIGHTS as of the EFFECTIVE DATE and all other INTELLECTUAL PROPERTY owned by, either partially or wholly, or licensed to, or otherwise controlled by, OREXIGEN as of the EFFECTIVE DATE necessary to practice the OREXIGEN PATENT RIGHTS and all INTELLECTUAL PROPERTY, excluding those defined in subsection 1.25(A) of this AGREEMENT, owned by, either partially or wholly, or licensed to, or otherwise controlled by, OREXIGEN as of the EFFECTIVE DATE useful to practice the OREXIGEN PATENT RIGHTS.
 
  1.42   RESPONDENT” shall have the meaning given in Section 20.04(a).
 
  1.43   RESPONDENT’S PROPOSAL” shall have the meaning given in Section 20.04(b).
 
  1.44   REPONSE” shall have the meaning given in Section 20.04(a).
 
  1.45   RUNNING ROYALTY” shall have the meaning given in Section 3.01(b).
 
  1.46   SUBLICENSE” and “SUBLICENSE AGREEMENT” means any relationship/agreement in which a THIRD PARTY gains any rights, temporary or otherwise, to any of the rights granted by OREXIGEN to CYPRESS under this AGREEMENT (including, but not limited to, CYPRESS AFFILIATES, assignee(s), licensee(s), sublicensee(s), marketing partner(s) and the like, hereinafter, such THIRD PARTIES referred as “SUBLICENSEES”), including, but not limited to those granted via options, rights of first refusal, material transfer agreements, sublicenses (implied or expressed), and the like, but excluding any THIRD PARTY that purchases LICENSED PRODUCTS as the end user thereof.
 
  1.47   TERRITORY” means the world.
 
  1.48   THIRD PARTY” means any individual or other entity other than OREXIGEN and/or CYPRESS.
 
  1.49   VALID CLAIM” means (i) an issued and unexpired claim within the OREXIGEN PATENT RIGHTS that has not been permanently revoked or held

- 7 -